Related references
Note: Only part of the references are listed.Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
Ina Valeria Zurlo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer
Qing Li et al.
MOLECULAR THERAPY (2022)
Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
Yoshiyasu Umeda et al.
EUROPEAN JOURNAL OF CANCER (2021)
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
F. Pietrantonio et al.
ESMO OPEN (2021)
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Joao Alessi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
Mark A. Baxter et al.
BRITISH JOURNAL OF CANCER (2021)
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
Wei Mu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer
Mohammadhadi Khorrami et al.
CANCER IMMUNOLOGY RESEARCH (2020)
The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping
Alex Zwanenburg et al.
RADIOLOGY (2020)
Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
Houssein Abdul Sater et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer
Y. Jiang et al.
ANNALS OF ONCOLOGY (2020)
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
A. Simonaggio et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer
Yixin Zhou et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma
Hao Peng et al.
CLINICAL CANCER RESEARCH (2019)
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten et al.
IMMUNITY (2019)
The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications
B. Soldevilla et al.
EUROPEAN JOURNAL OF CANCER (2019)
Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas
Niha Beig et al.
RADIOLOGY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun et al.
LANCET ONCOLOGY (2018)
Radiomics signature of computed tomography imaging for prediction of survival and chemotherapeutic benefits in gastric cancer
Yuming Jiang et al.
EBIOMEDICINE (2018)
Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Yuming Jiang et al.
CLINICAL CANCER RESEARCH (2018)
ImmunoScore Signature A Prognostic and Predictive Tool in Gastric Cancer
Yuming Jiang et al.
ANNALS OF SURGERY (2018)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Radiomics: the bridge between medical imaging and personalized medicine
Philippe Lambin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer
Yuming Jiang et al.
JAMA SURGERY (2017)
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
E. J. Limkin et al.
ANNALS OF ONCOLOGY (2017)
Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
Nathaniel M. Braman et al.
BREAST CANCER RESEARCH (2017)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Radiomics: Images Are More than Pictures, They Are Data
Robert J. Gillies et al.
RADIOLOGY (2016)
The patterns and timing of recurrence after curative resection for gastric cancer in China
Dan Liu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2016)
Neutrophils in cancer: neutral no more
Seth B. Coffelt et al.
NATURE REVIEWS CANCER (2016)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
D. Lorente et al.
ANNALS OF ONCOLOGY (2015)
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Tissue-Infiltrating Neutrophils Constitute the Major In Vivo Source of Angiogenesis-Inducing MMP-9 in the Tumor Microenvironment
Elena I. Deryugina et al.
NEOPLASIA (2014)
The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer
Graeme J. K. Guthrie et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
The tumor microenvironment controls drug sensitivity
Arne Ostman
NATURE MEDICINE (2012)
Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth
A. McGarry Houghton et al.
NATURE MEDICINE (2010)
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8
H Schaider et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Share Paper
